prr v dndn, page-8

Hi Chiswell,

In short PRR's CVac is a immunotherapeutic product based on the same celluar technology as DNDN's Provenge.

Two points worth considering amongst many positives for CVac are:

The FDA approval of Provenge has paved the way for Cvac. This is not just a catch phrase, it's a fact!

For example, once the first monoclonal antibody was approved by the FDA it opened the way for many more approvals.

Secondly, Cvac could be much bigger than Provenge! Provenge targets prostrate cancer while Cvac may end up targeting ovarian, breast, lung, colon, and pancreatic cancer.